CRNX NASDAQ
Crinetics Pharmaceuticals, Inc.
1W: -3.2%
1M: -5.1%
3M: -14.6%
YTD: -20.6%
1Y: +18.2%
3Y: +67.8%
5Y: +128.7%
$36.80
-0.29 (-0.78%)
Weekly Expected Move ±8.8%
$30
$34
$37
$40
$43
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (53)
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday
Crinetics (CRNX) Q1 2026 Earnings Transcript
Crinetics outlines plan to exceed 75% Palsonify coverage by end of Q3 2026 while funding operations into 2030
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Analysts Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Price Target at $76.63
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Analysts
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Crinetics Pharma COO to step down
Most oversold mid-cap healthcare stocks on Wall Street amid Middle East disruptions
Intech Investment Management LLC Has $926,000 Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX
Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $74.78
American Century Companies Inc. Has $47.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics outlines $600M–$650M 2026 operating expense plan as PALSONIFY launch accelerates
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals GAAP EPS of -$1.29 beats by $0.07, revenue of $6.1M beats by $1.36M
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Squarepoint Ops LLC Has $1.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Capital Fund Management S.A. Makes New $424,000 Investment in Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
Creative Planning Sells 1,445 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
Geode Capital Management LLC Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome